{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T06:20:47Z","timestamp":1788675647180,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.jaad.2023.05.076","type":"journal-article","created":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T12:38:05Z","timestamp":1686400685000},"page":"694-702","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["A proof-of-concept open-label clinical trial of spleen tyrosine kinase antagonism using fostamatinib in moderate-to-severe hidradenitis suppurativa"],"prefix":"10.1016","volume":"89","author":[{"given":"Rebecca","family":"Jepsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Flora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Kozera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Frew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2023.05.076_bib1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","article-title":"Hidradenitis suppurativa","volume":"6","author":"Sabat","year":"2020","journal-title":"Nat Rev Dis Prim"},{"issue":"2","key":"10.1016\/j.jaad.2023.05.076_bib2","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jid.2020.06.019","article-title":"A systematic review of promising therapeutic targets in hidradenitis suppurativa: a critical evaluation of mechanistic and clinical relevance","volume":"141","author":"Frew","year":"2021","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2023.05.076_bib3","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"issue":"10378","key":"10.1016\/j.jaad.2023.05.076_bib4","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.jaad.2023.05.076_bib5","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1001\/jamadermatol.2021.2905","article-title":"Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, Double-blind, placebo-controlled randomized clinical trial","volume":"157","author":"Glatt","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2023.05.076_bib6","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/bjd.19556","article-title":"Aetiology and pathogenesis of hidradenitis suppurativa","volume":"183","author":"Wolk","year":"2020","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2023.05.076_bib7","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.jaad.2020.05.007","article-title":"The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: an open-label cohort study","volume":"83","author":"Frew","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2023.05.076_bib8","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/bjd.19478","article-title":"Weekly administration of brodalumab in hidradenitis suppurativa: an open-label cohort study","volume":"184","author":"Frew","year":"2021","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2023.05.076_bib9","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/exd.14092","article-title":"Beyond antibodies: B-cells in hidradenitis suppurativa: bystanders, contributors or therapeutic targets?","volume":"29","author":"Frew","year":"2020","journal-title":"Exp Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2023.05.076_bib10","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.jid.2019.08.453","article-title":"Enrichment of plasma cell sin the peripheral blood and skin of patients with Hidradenitis suppurativa","volume":"140","author":"Musilova","year":"2020","journal-title":"J Invest Dermatol"},{"issue":"508","key":"10.1016\/j.jaad.2023.05.076_bib11","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav5908","article-title":"Neutrophil extracellular traps, B cells and type I interferons contribute to immune dysregulation in hidradenitis suppurativa","volume":"11","author":"Byrd","year":"2019","journal-title":"Sci Trans Med"},{"issue":"3 Pt B","key":"10.1016\/j.jaad.2023.05.076_bib12","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jid.2021.07.187","article-title":"Autoantibodies present in hidradenitis suppurativa correlate with disease severity and promote the release of proinflammatory cytokines in macrophages","volume":"142","author":"Carmona-Rivera","year":"2022","journal-title":"J Invest Dermatol"},{"issue":"19","key":"10.1016\/j.jaad.2023.05.076_bib13","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139932","article-title":"Immunopathogenesis of hidradenitis suppurativa and response to anti-TNF-alpha therapy","volume":"5","author":"Lowe","year":"2020","journal-title":"JCI Insight"},{"issue":"19","key":"10.1016\/j.jaad.2023.05.076_bib14","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139930","article-title":"Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis","volume":"5","author":"Gudjonsson","year":"2020","journal-title":"JCI Insight"},{"issue":"10","key":"10.1016\/j.jaad.2023.05.076_bib15","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s40267-018-0551-x","article-title":"Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA","volume":"34","author":"McKeage","year":"2018","journal-title":"Drugs Ther Perspect"},{"issue":"7","key":"10.1016\/j.jaad.2023.05.076_bib16","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel","year":"2018","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.jaad.2023.05.076_bib17","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ajh.26508","article-title":"Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: phase 2, multicenter, open-label study","volume":"97","author":"Kuter","year":"2022","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.jaad.2023.05.076_bib18","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/jdv.13216","article-title":"HiSCR (Hidradenitis suppurativa clinical response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study","volume":"30","author":"Kimball","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.jaad.2023.05.076_bib19","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/bjd.15748","article-title":"Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity","volume":"177","author":"Zouboulis","year":"2017","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2023.05.076_bib20","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1111\/bjd.18309","article-title":"Defining lesional, perilesional and unaffected skin in hidradenitis suppurativa: proposed recommendations for clinical trials and translational research studies","volume":"181","author":"Frew","year":"2019","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2023.05.076_bib21","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2023.05.076_bib22","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/s41419-021-04403-2","article-title":"Targeting SYK of monocyte-derived macrophages regulates liver fibrosis via crosstalking with Erk\/Hif1\u03b1 and remodeling liver inflammatory environment","volume":"12","author":"Chen","year":"2021","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jaad.2023.05.076_bib23","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.12688\/f1000research.17267.1","article-title":"A systematic review and critical evaluation of inflammatory cytokine associations in hidradenitis suppurativa","volume":"7","author":"Frew","year":"2018","journal-title":"F1000Res"},{"key":"10.1016\/j.jaad.2023.05.076_bib24","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.3389\/fimmu.2019.01862","article-title":"Tyrosine kinases in autoimmune and inflammatory skin diseases","volume":"10","author":"Szilveszter","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jaad.2023.05.076_bib25","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nrd.2017.267","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"17","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"22","key":"10.1016\/j.jaad.2023.05.076_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232213800","article-title":"Serum immunoglobulin G is a marker of hidradenitis suppurativa disease severity","volume":"23","author":"Mintoff","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.jaad.2023.05.076_bib27","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1001\/jamadermatol.2021.4926","article-title":"Identification of biomarkers and critical evaluation of biomarker validation in hidradenitis suppurativa: a systematic review","volume":"158","author":"Der Sarkissian","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2023.05.076_bib28","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jaad.2019.12.044","article-title":"Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: a post hoc analysis of PIONEER 1 and 2 individual patient data","volume":"82","author":"Frew","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2023.05.076_bib29","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jdin.2020.09.005","article-title":"Quantifying the natural variation in lesion counts over time in untreated Hidradenitis Suppurativa: implications for outcome measures and trial design","volume":"1","author":"Frew","year":"2020","journal-title":"JAAD Int"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223010824?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223010824?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:28:52Z","timestamp":1759274932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962223010824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0190962223010824"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2023.05.076","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A proof-of-concept open-label clinical trial of spleen tyrosine kinase antagonism using fostamatinib in moderate-to-severe hidradenitis suppurativa","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2023.05.076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}